86 completed, 28 recruiting, 26 terminated, 17 active not recruiting. 189 Phase 1, 71 Phase 2.
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer Disitamab Vedotin, Toripalimab, Cetirizine - Bladder Cancer | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 20 | 2027-01-01 | 2026-10-01 |
| Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) ATO-101™ - Bladder Cancer | Phase 1 | Not yet recruiting | Institut Cancerologie de l'Ouest | 24 | 2027-01-01 | 2026-06-08 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure Intravesical Instillation of Disitamab Vedotin Combined with Toripalimab - Bladder Cancer | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | 20 | 2026-09-01 | 2026-08-25 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155 - Breast Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Novartis Pharmaceuticals | 156 | 2026-06-16 | 2026-08-27 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma EB-DT-NK-UC101, Cyclophosphamide, Fludarabine - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-03-25 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) MK-3120 - Bladder Cancer, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 45 | 2025-12-09 | 2026-10-29 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors CP-383 - Solid Tumor Malignancies, Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Tasca Therapeutics | 150 | 2025-08-27 | 2026-02-18 |
| IDOV-Immune for Advanced Solid Tumors IDOV-Immune (oncolytic vaccinia virus) - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Recruiting | ViroMissile, Inc. | 78 | 2025-08-25 | 2026-08-05 |
| A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors PF-08046876, Pembrolizumab, Cisplatin - Advanced/Metastatic Solid Tumors, Bladder Cancer | Phase 1 | Recruiting | Pfizer | 540 | 2025-08-20 | 2026-10-13 |
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents Romidepsin, Durvalumab - Bladder Cancer | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2025-06-24 | 2026-10-30 |
Showing 20 of 189. Sign in to see all of them.
Urinary Bladder Neoplasms (189) · Carcinoma, Non-Small-Cell Lung (53) · Ovarian Neoplasms (53) · Breast Neoplasms (38) · Colorectal Neoplasms (38) · Stomach Neoplasms (38) · Melanoma (37) · Pancreatic Neoplasms (35) · Prostatic Neoplasms (35) · Carcinoma, Renal Cell (30) · Esophageal Neoplasms (29) · Lung Neoplasms (29) · Squamous Cell Carcinoma of Head and Neck (27) · Triple Negative Breast Neoplasms (27) · Neoplasm Metastasis (26)
Female Urogenital Diseases (189) · Female Urogenital Diseases and Pregnancy Complications (189) · Male Urogenital Diseases (189) · Neoplasms by Site (189) · Urogenital Diseases (189) · Urinary Bladder Diseases (186) · Urologic Diseases (186) · Urogenital Neoplasms (185) · Urologic Neoplasms (181) · Neoplasms (168) · Neoplasms by Histologic Type (109) · Neoplasms, Glandular and Epithelial (98) · Carcinoma (91) · Lung Diseases (74) · Respiratory Tract Diseases (74)
pembrolizumab (25) · Gemcitabine (23) · Cisplatin (17) · Paclitaxel (11) · Carboplatin (7) · Docetaxel (7) · enfortumab vedotin (7) · atezolizumab (6) · durvalumab (6) · Nivolumab (5) · Radiotherapy (5) · tremelimumab (5) · Filgrastim (4) · Albumin-Bound Paclitaxel (3) · BCG Vaccine (3)
Memorial Sloan Kettering Cancer Center (11) · M.D. Anderson Cancer Center (4) · Pfizer (4) · Baylor College of Medicine (3) · Celldex Therapeutics (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Incyte Corporation (3) · MacroGenics (3) · Merck Sharp & Dohme LLC (3) · National Cancer Institute (NCI) (3) · Seagen Inc. (3) · ADC Therapeutics S.A. (2) · Arcus Biosciences, Inc. (2) · Cancer Research UK (2) · Eli Lilly and Company (2)
United States (126) · Australia (24) · China (23) · United Kingdom (23) · Spain (19) · Canada (16) · France (13) · Belgium (8) · Italy (8) · South Korea (7) · Denmark (6) · Israel (6) · Germany (5) · Japan (5) · Netherlands (5)
Dean F. Bajorin, MD (3) · Gary Steinberg, MD (2) · Johann de Bono, Professor (2) · Abai Xu, doctor (1) · Adrian L. Harris, MD (1) · Aihua Edward Yen, MD (1) · Al B. Benson, MD, FACP (1) · Alan I So, MD, FRCSC (1) · Alan Pantuck, MD (1) · Alexander Prokhorov, Dr (1) · Ali Abdalvand, MD (1)
PMID 37496366, PMID 41044356, PMID 15928663, PMID 17409436, PMID 17452976, PMID 18245546, PMID 19100600, PMID 19636012, PMID 19706807, PMID 20407240, PMID 22461641, PMID 24668644, PMID 25366678, PMID 25747273, PMID 26228759, PMID 26871284, PMID 29322091, PMID 29735994, PMID 30552156, PMID 30745090, PMID 31320352, PMID 31796521, PMID 33199155, PMID 35012889, PMID 35089812, PMID 35929986, PMID 36084396, PMID 36441083, PMID 36600561, PMID 36669791, PMID 36803840, PMID 37082579, PMID 37469327, PMID 37651261, PMID 37871703, PMID 38155060, PMID 38573872, PMID 39069239, PMID 39462179, PMID 39521884, PMID 39726590, PMID 39762422, PMID 39886141, PMID 39920391, PMID 40830709, PMID 40973049, PMID 42201333
2019 (3), 2023 (3), 2025 (3), 2017 (2), P50CA091846 (2), 2009 (1), 2014 (1), 2016 (1), 2018 (1), P30CA016672 (1), P30CA023108 (1), P30CA138292 (1), UL1TR002366 (1)